logo-loader

Orgenesis gets Orphan Drug designation to treat severe diabetes

Published: 02:40 29 Jun 2019 AEST

Orgenesis Inc (NASDAQ:ORGS) Chief Scientific Officer Dr. Sarah Ferber tells Proactive Investors the FDA has granted Orphan Drug designation to its Autologous Insulin Producing (AIP) cells as a cell-replacement therapy for the treatment of severe diabetes following a pancreatectomy, a surgical procedure performed to treat chronic pancreatitis.

According to Dr. Ferber, the Maryland-based biopharmaceutical company’s Israeli subsidiary, Orgenesis Ltd, has already gained approval to analyze the safety of targeting insulin-dependent diabetes.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

6 hours, 57 minutes ago